Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia

Bibliography

• Tack J, Talley NJ, Camilleri M, Functional gastroduodenal disorders. Gastroenterology 2006;130(5):1466-79
   PubMed Web of Science ®Google Scholar
• Brook RA, Kleinman NL, Choung RS, Functional dyspepsia impacts absenteeism and direct and indirect costs. Clin Gastroenterol Hepatol 2010;8(6):498-503
   PubMed Web of Science ®Google Scholar
• Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004;127:1239-55
   PubMed Web of Science ®Google Scholar
• Van Oudenhove L, Vandenberghe J, Geeraerts B, Determinants of symptoms in functional dyspepsia: gastric sensorimotor function, psychosocial factors or somatisation? Gut 2008:57(12):1666-76
   PubMed Web of Science ®Google Scholar
• Karamanolis G, Tack J. Promotility medications–now and in the future. Dig Dis 2006;24(3-4):297-307
   PubMed Web of Science ®Google Scholar
• Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol 2008;8(6):690-6
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Soo S, Deeks J, Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006;18(4):CD001960
   Google Scholar
• Talley NJ, Verlinden M, Snape W, Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000;14:1653-61
   PubMed Web of Science ®Google Scholar
• Talley NJ, Tack J, Ptak T, Itopride in functional dyspepsia: results of two phase III multicenter, randomized, double-blind, placebo-controlled trials. Gut 2008;57:740-6
   PubMed Web of Science ®Google Scholar
• Vakil N, Talley NJ, Zakko S, Tegaserod treatment for functional dyspepsia dysmotility symptoms: results of two randomized, controlled trials. Am J Gastroenterol 2008;103(8):1906-19
   PubMed Web of Science ®Google Scholar
• Ogishima M, Kaibara M, Ueki S, Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach. J Pharmacol Exp Ther 2000;294:33-7
   PubMed Web of Science ®Google Scholar
• Nakajima T, Nawata H, Ito Y. Z-338, a newly synthetized carboxyamide derivative, stimulates gastric motility through enhancing the excitatory neurotransmission. J Smooth Muscle Res 2000;36:69-81
   PubMedGoogle Scholar
• Doi Y, Murasaki O, Kaibara M, Characterization of functional effect of Z-338, a novel gastroprokinetic agent, on the muscarinic M1, M2, and M3 receptors expressed in Xenopus oocytes. Eur J Pharmacol 2004;505:31-5
   PubMed Web of Science ®Google Scholar
• Matsunaga Y, Tanaka T, Yoshinaga K, Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride and mosapride. Submitted for publication, 2010
   Google Scholar
• Di Stefano M, Vos R, Klersy C, Neostigmine-induced postprandial phasic contractility in the proximal stomach and dyspepsia-like symptoms in healthy volunteers. Am J Gastroenterol 2006;101(12):2797-804
   PubMed Web of Science ®Google Scholar
• Kindt S, Tack J. Impaired gastric accommodation and its role in dyspepsia. Gut 2006;55:1685-91
   PubMed Web of Science ®Google Scholar
• Oliver SD, Ward C, Ward J, Z-338: phase I, single and multiple oral dose, safety, tolerability and pharmacokinetic studies in healthy male subjects. Abstracts of the Joint Meeting of VII World Conference on Clinical Pharmacology and Therapeutics IUPHAR – Division of Clinical Pharmacology & 4th Congress of the European Association for Clinical Pharmacology and Therapeutics; 2000. p. 244
   Google Scholar
• Seto K, Sasaki T, Katsunuma K, Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil 2008;20:1051-9
   PubMed Web of Science ®Google Scholar
• Adam B, Liebregts T, Zschau NB, Z-338 improves meal-induced symptoms in functional dyspepsia: a double-blind, randomized, placebo controlled crossover study [abstract]. Gastroenterology 2009;136:A535
   Web of Science ®Google Scholar
• Kusunoki H, Haruma K, Imamura H, Therapeutic efficacy of Z-338 (Acotiamide Hydrochloride) in patients with functional dyspepsia is based on enhanced post-prandial gastric accommodation and emptying: confirmed by real-time ultrasonography. Gastroenterology 2010;138(5 Suppl 1):S154-5
   Google Scholar
• Tack J, Masclee A, Heading R, A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil 2009;21(3):272-80
   PubMed Web of Science ®Google Scholar
• Matsueda K, Hongo M, Sasaki D, Therapeutic efficacy of novel agent (Z-338) in functional dyspepsia. Gastroenterology 2005;128:A467
   Web of Science ®Google Scholar
• Talley NJ, Tack J, Kowalski D, A novel acetylcholine esterase inhibitor acotiamide hydrochloride (YM443) in functional dyspepsia: efficacy in a randomized, double-blind, placebo-controlled dose ranging trial [abstract]. Gastroenterology 2008;134:A-157
   Google Scholar
• Tack J, Talley NJ, Kowalski D, Influence of PPI run-in, pH monitoring and nutrient tolerance on efficacy outcomes of acotiamide hydrochloride (YM443), a novel acetylcholine esterase inhibitor, in functional dispepsia [abstract]. Gastroenteroloy 2008;134:A143
   Web of Science ®Google Scholar
• Tack J, Caenepeel P, Piessevaux H, Assessment of meal-induced gastric accommodation by a satiety drinking test in health and in functional dyspepsia. Gut 2003;52:1271-7
   PubMed Web of Science ®Google Scholar
• Matsueda K, Hongo M, Tack J, Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil 2010;22:618-e173
   PubMed Web of Science ®Google Scholar
• Talley NJ, Stanghellini V, Heading RC, Functional gastroduodenal disorders. Gut 1999;45(Suppl 2):II37-42
   PubMedGoogle Scholar
• Available from: http://www.zeria.co.jp/english/pdf/press20090303.pdf
   Google Scholar
• Available from: http://www.zeria.co.jp/english/pdf/press20100628.pdf
   Google Scholar
• Available from: http://www.zeria.co.jp/english/pdf/press20100929.pdf
   Google Scholar
• Parkman HP, Trate DM, Knight LC, Cholinergic effects on human gastric motility. Gut 1999;45(3):346-54
   PubMed Web of Science ®Google Scholar